Evogene (EVGN) Income from Continuing Operations (2016 - 2025)
Historic Income from Continuing Operations for Evogene (EVGN) over the last 14 years, with Q3 2025 value amounting to -$2.7 million.
- Evogene's Income from Continuing Operations rose 5956.72% to -$2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.3 million, marking a year-over-year increase of 6324.9%. This contributed to the annual value of -$14.8 million for FY2024, which is 4291.05% up from last year.
- According to the latest figures from Q3 2025, Evogene's Income from Continuing Operations is -$2.7 million, which was up 5956.72% from -$3.5 million recorded in Q2 2025.
- In the past 5 years, Evogene's Income from Continuing Operations registered a high of $983000.0 during Q4 2024, and its lowest value of -$9.8 million during Q2 2022.
- Its 5-year average for Income from Continuing Operations is -$5.8 million, with a median of -$6.9 million in 2021.
- In the last 5 years, Evogene's Income from Continuing Operations tumbled by 9201.78% in 2023 and then skyrocketed by 11339.78% in 2024.
- Evogene's Income from Continuing Operations (Quarter) stood at -$8.1 million in 2021, then soared by 52.73% to -$3.8 million in 2022, then crashed by 92.02% to -$7.3 million in 2023, then skyrocketed by 113.4% to $983000.0 in 2024, then plummeted by 377.52% to -$2.7 million in 2025.
- Its Income from Continuing Operations was -$2.7 million in Q3 2025, compared to -$3.5 million in Q2 2025 and -$3.0 million in Q1 2025.